BioIndustry Ethics
- Publisher's listprice EUR 38.95
-
16 154 Ft (15 385 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 10% (cc. 1 615 Ft off)
- Discounted price 14 539 Ft (13 847 Ft + 5% VAT)
Subcribe now and take benefit of a favourable price.
Subscribe
16 154 Ft
Availability
Uncertain availability. Please turn to our customer service.
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Publisher Academic Press
- Date of Publication 19 July 2005
- ISBN 9780123693709
- Binding Paperback
- No. of pages384 pages
- Size 229x152 mm
- Weight 610 g
- Language English 0
Categories
Long description:
This book is the first systematic, detailed treatment of the approaches to ethical issues taken by biotech and pharmaceutical companies. The application of genetic/genomic technologies raises a whole spectrum of ethical questions affecting global health that must be addressed. Topics covered in this comprehensive survey include considerations for bioprospecting in transgenics, genomics, drug discovery, and nutrigenomics, as well as how to improve stakeholder relations, design ethical clinical trials, avoid conflicts of interest, and establish ethics advisory boards. The expert authors represent multiple disciplines including law, medicine, bioinformatics, pharmaceutics, business, and ethics.
"Biotechnology and pharmaceutical companies are often driven by profit goals, but the case studies in Bioindustry Ethics show that this is increasingly not at the expense of ethical integrity. ...lend[s] important insights to other executives and professionals who might be developing their own practices and policies."
- GENOMICS & PROTEOMICS (August 2005)
Table of Contents:
Chapter 1: INTRODUCTION
Chapter 2: MERCK: STAYING THE COURSE
Chapter 3: GENZYME: PUTTING PATIENTS FIRST
Chapter 4: MILLENNIUM PHARMACEUTICALS, INC.: CREATING AND SUSTAINING CORPORATE VALUES
Chapter 5: MAXIM PHARMACEUTICALS (A): INTERNAL AND EXTERNAL DIALOGUES
Chapter 6: DIVERSA INC.: ETHICAL ISSUES IN BIOPROSPECTING PARTNERSHIPS
Chapter 7: PIPELINE BIOTECH A/S: COMPETING REGULATORY REGIMES FOR LABORATORY ANIMAL EXPERIMENTS
Chapter 8: TGN BIOTECH: A START-UP WITH ETHICAL ROOTS
Chapter 9: INTERLEUKIN GENETICS AND ALTICOR: AN UNLIKELY PARTNERSHIP
Chapter 10: SCIONA LTD.: A PIONEER IN NUTRIGENOMICS: THE PATH TO CONSUMER ACCEPTANCE
Chapter 11: AFFYMETRIX, INC.: USING CORPORATE ETHICS ADVICE
Chapter 12: PHARMASNPS INC.: CREATING AN ETHICS ADVISORY BOARD
Chapter 13: MONSANTO COMPANY: BIO-AGRICULTURE PIONEER
Chapter 14: NOVO NORDISK: THE TRIPLE BOTTOM LINE
Chapter 15: CONCLUSION: LESSONS FOR COMPANIES AND FUTURE ISSUES
INDEX
More
